SELLAS Life Sciences Group Inc (SLS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
89
About the Report
About the Report
Summary
SELLAS Life Sciences Group Inc (SELLAS), formerly Galena Biopharma Inc, is a clinical-stage biopharmaceutical company that develops novel cancer immunotherapeutics for a broad range of cancer indications. Its lead product candidate, galinpepimut-S, is a Wilms Tumor 1 (WT1) protein-targeting synthetic heteroclitic epitope immunotherapeutic antigen used for the treatment of acute myeloid leukemia (AML), ovarian cancer, malignant pleural mesothelioma (MPM), multiple myeloma, and solid tumors. Its pipeline includes NeuVax (nelipepimut-S), a vaccine derived from the human epidermal growth factor 2 or HER2-protein to treat breast cancer; GALE-301 and GALE-302, vaccines derived from the folate binding protein (FBP) to treat ovarian cancer; and GALE-401, a controlled release anagrelide for thrombocythemia. SELLAS is headquartered in New York City, New York, the US.
SELLAS Life Sciences Group Inc (SLS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
SELLAS Life Sciences Group Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
SELLAS Life Sciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 11
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 14
Partnerships 16
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 16
Galena Biopharma Enters into Agreement with National Cancer Institute 17
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 18
Licensing Agreements 19
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 19
Sellas Life Sciences Enters into Licensing Agreement with Trojantec 20
Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences 21
Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 22
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 23
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 24
BioVascular Amends Licensing Agreement with Mills Pharma 25
Equity Offering 26
SELLAS Life Sciences Raises USD24.2 Million in Public Offering of Shares 26
SELLAS Life Sciences Plans to Raise USD18 Million in Public Offering of Shares 28
SELLAS Life Sciences Raises USD4.6 Million in Second Tranche of Private Placement of Preferred Stock and Warrants 29
SELLAS Life Sciences Raises USD6 Million in First Tranche of Private Placement of Preferred Stock and Warrants 30
Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 31
Galena Biopharma to Raise Funds in Public Offering of Shares 33
Galena Biopharma Raises USD12.6 Million in Private Placement of Shares and Warrants 34
Galena Biopharma Raises USD21.8 Million in Public Offering of Units 35
Galena Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD43 Million 37
Galena Biopharma Raises USD5 Million in First Tranche of Private Placement of Shares 39
Galena Biopharma Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Units For USD 40 Million 41
Galena Biopharma Completes Public Offering Of Units For USD 24 Million 43
Galena Biopharma Completes Public Offering Of Common Stock For USD 14.5 Million 45
Debt Offering 47
Galena Biopharma Raises USD25 Million in Private Placement of Debentures 47
Asset Transactions 48
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 48
Sentynl Therapeutics Acquires Abstral from Galena Biopharma 49
Acquisition 50
Galena Biopharma Acquires SELLAS Life Sciences 50
Galena Biopharma Acquires Mills Pharma 52
SELLAS Life Sciences Group Inc-Key Competitors 53
SELLAS Life Sciences Group Inc-Key Employees 54
SELLAS Life Sciences Group Inc-Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Recent Developments 56
Financial Announcements 56
Apr 16, 2018: SELLAS Life Sciences Reports Corporate Highlights, Advancements for its Cancer Immunotherapy Pipeline and 2017 Financial Results 56
Nov 09, 2017: Galena Biopharma Reports Third Quarter 2017 Financial Results 58
Aug 14, 2017: Galena Biopharma Reports Second Quarter 2017 Financial Results 60
May 10, 2017: Galena Biopharma Reports First Quarter 2017 Financial Results 63
Mar 15, 2017: Galena Biopharma Reports Fourth Quarter and Year End 2016 Financial Results and Provides a Corporate Update 66
Corporate Communications 70
Apr 20, 2018: SELLAS Life Sciences Announces Appointment Of Gene Mack As Chief Financial Officer And Treasurer 70
Mar 21, 2018: SELLAS Life Sciences Announces Appointment of Barbara A. Wood as Executive Vice President, General Counsel and Corporate Secretary 71
Feb 01, 2018: Women In Bio Announces Jane Wasman Appointed Chair of Sellas Life Sciences' Board of Directors 72
Feb 21, 2017: Galena Biopharma Board of Directors Appoints Stephen F. Ghiglieri as Interim Chief Executive Officer 73
Jan 31, 2017: Galena Biopharma Announces the Resignation of its President and Chief Executive Officer and the Evaluation of Strategic Alternatives 74
Product News 75
03/17/2017: Galena Biopharma Presents Positive Final GALE-301 (E39) Phase 1/2a Clinical Trial Data 75
Product Approvals 76
May 09, 2018: SELLAS Life Sciences Receives FDA Orphan Drug Designation for Galinpepimut-S (GPS) for Treatment of Multiple Myeloma (MM) 76
Clinical Trials 77
Jun 04, 2018: SELLAS Life Sciences Presents Interim Phase 1 Clinical Data of Galinpepimut-S (GPS) in Combination with Nivolumab to Treat Wilms Tumor 1 Positive (WT1+) Ovarian Cancer Patients at ASCO 2018 77
May 17, 2018: SELLAS Life Sciences to Present Phase 1/2 Clinical Data of Galinpepimut-S (GPS) in Ovarian Cancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 79
Mar 19, 2018: SELLAS Life Sciences Phase 2 Results for Galinpepimut-S in High-Risk Multiple Myeloma Presented at European Society for Blood and Marrow Transplantation Meeting 80
Feb 27, 2018: Data From SELLAS Life Sciences' Positive Phase 2 Acute Myeloid Leukemia Study Published in American Society of Hematology's Journal, Blood Advances 81
Jan 24, 2018: SELLAS Life Sciences Group to Present Complete Phase 2 Correlative Results for its Lead Cancer Immunotherapy Candidate, galinpepimut-S (GPS), in Treatment of Multiple Myeloma: Oral Presentation at the 2018 European Society for Blood and Marrow Transplantation Meeting 82
Sep 14, 2017: SELLAS Galinpepimut-S Induces Specific, Robust and Durable Immune Responses in Patients With High-Risk Multiple Myeloma-Correlated With Clinical Benefit 83
Mar 01, 2017: SELLAS Life Sciences Announces Updated Positive Phase 2 Data Reinforcing Meaningful Clinical Benefit of its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients 84
Other Significant Developments 86
Jul 12, 2017: Galena Biopharma Provides Corporate Update 86
Mar 09, 2017: Galena Biopharma Engages Canaccord Genuity to Advise on Strategic Alternatives 87
Jan 05, 2017: Galena Biopharma to Provide Corporate and Clinical Update and 2017 Outlook During Presentation at Biotech Showcase 2017 88
Appendix 89
Methodology 89
About GlobalData 89
Contact Us 89
Disclaimer 89
List of Figure
List of Figures
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
SELLAS Life Sciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 11
List of Table
List of Tables
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
SELLAS Life Sciences Group Inc, Deals By Therapy Area, 2012 to YTD 2018 10
SELLAS Life Sciences Group Inc, Medical Devices Deals, 2012 to YTD 2018 11
SELLAS Life Sciences Group Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Galena Biopharma Acquires Abstral Sublingual Tablets From Orexo 14
SELLAS Life Sciences Enters into Clinical Trial Agreement with Merck 16
Galena Biopharma Enters into Agreement with National Cancer Institute 17
Galena Biopharma Enters Into Commercialization Agreement With Teva Pharma For NeuVax 18
Sellas Life Sciences Enters into Licensing Agreement with Advaxis 19
Sellas Life Sciences Enters into Licensing Agreement with Trojantec 20
Catalent Pharma Solutions Enters into Licensing Agreement with Sellas Life Sciences 21
Sellas Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center for Vaccine to Target WT1 for Cancer 22
Monosol Rx Enters into Licensing Agreement with Galena Biopharma for Zuplenz 23
Galena Biopharma Enters Into Licensing Agreement With Dr. Reddy's Labs For NeuVax 24
BioVascular Amends Licensing Agreement with Mills Pharma 25
SELLAS Life Sciences Raises USD24.2 Million in Public Offering of Shares 26
SELLAS Life Sciences Plans to Raise USD18 Million in Public Offering of Shares 28
SELLAS Life Sciences Raises USD4.6 Million in Second Tranche of Private Placement of Preferred Stock and Warrants 29
SELLAS Life Sciences Raises USD6 Million in First Tranche of Private Placement of Preferred Stock and Warrants 30
Galena Biopharma Raises Up to USD15.5 Million in Public Offering of Shares and Warrants 31
Galena Biopharma to Raise Funds in Public Offering of Shares 33
Galena Biopharma Raises USD12.6 Million in Private Placement of Shares and Warrants 34
Galena Biopharma Raises USD21.8 Million in Public Offering of Units 35
Galena Biopharma Completes Underwriters Exercise of Over-Allotment Option of Public Offering of Shares and Warrants for USD43 Million 37
Galena Biopharma Raises USD5 Million in First Tranche of Private Placement of Shares 39
Galena Biopharma Completes Underwriters Exercise Of Full Over-Allotment Option Of Public Offering Of Units For USD 40 Million 41
Galena Biopharma Completes Public Offering Of Units For USD 24 Million 43
Galena Biopharma Completes Public Offering Of Common Stock For USD 14.5 Million 45
Galena Biopharma Raises USD25 Million in Private Placement of Debentures 47
Midatech Pharma Acquires Zuplenz from Galena Biopharma for up to USD29.7 Million 48
Sentynl Therapeutics Acquires Abstral from Galena Biopharma 49
Galena Biopharma Acquires SELLAS Life Sciences 50
Galena Biopharma Acquires Mills Pharma 52
SELLAS Life Sciences Group Inc, Key Competitors 53
SELLAS Life Sciences Group Inc, Key Employees 54
SELLAS Life Sciences Group Inc, Other Locations 55
SELLAS Life Sciences Group Inc, Subsidiaries 55
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.